Approval based on DUO-E trial results, which showed IMFINZI reduced the risk of disease progression or death by 58% vs. chemotherapy WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s IMFINZI® ...
Results showed a DFS benefit with the addition of pembrolizumab to chemotherapy for patients with mismatch repair-deficient tumors. The rate of grade 3 or greater adverse events was slightly higher ...
Patients with mismatch repair deficient gastric cancer demonstrated better median overall survival when skipping perioperative chemotherapy, according to a preprint study. Median overall survival is ...
Please provide your email address to receive an email when new articles are posted on . Dostarlimab conferred clinical complete responses in all patients treated during a phase 2 trial.. Circulating ...
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01) The National Cancer Institute ...
Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo ...
Maureen Sideris was driving to Maine for a wedding when she realized she couldn’t swallow the sandwich she was having for lunch. The 71-year-old was soon diagnosed with gastroesophageal cancer. It was ...
Tumors with mismatch repair deficiency (MMR-d) are characterized by sequence alterations in microsatellites and can accumulate thousands of mutations. This high mutational burden renders tumors ...
PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) today announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback